Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There's no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).

Market Analysis and Insights: Global Primary Biliary Cholangitis Treatment Market
The global Primary Biliary Cholangitis Treatment market size is projected to reach US$ 2500 million by 2027, from US$ 654.2 million in 2020, at a CAGR of 20.6% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Primary Biliary Cholangitis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Primary Biliary Cholangitis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Primary Biliary Cholangitis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Primary Biliary Cholangitis Treatment market.

Global Primary Biliary Cholangitis Treatment Scope and Market Size
Primary Biliary Cholangitis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Primary Biliary Cholangitis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (Ocaliva)

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals